Arcellx presents continued robust long-term responses from its CART-ddBCMA Ph1 expansion trial Clinical Impact Dec 13 Written By Frances Benson https://arcellx.com/arcellx-presents-continued-robust-long-term-responses-from-its-cart-ddbcma-phase-1-expansion-trial-in-patients-with-relapsed-or-refractory-multiple-myeloma-at-the-63rd-ash-annual-meeting-and-expositio/ 2021 Frances Benson
Arcellx presents continued robust long-term responses from its CART-ddBCMA Ph1 expansion trial Clinical Impact Dec 13 Written By Frances Benson https://arcellx.com/arcellx-presents-continued-robust-long-term-responses-from-its-cart-ddbcma-phase-1-expansion-trial-in-patients-with-relapsed-or-refractory-multiple-myeloma-at-the-63rd-ash-annual-meeting-and-expositio/ 2021 Frances Benson
